Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valopicitabine and Ribavirin Interaction in Hepatitis C
NCT00395421Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of valopicitabine in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoint: Pharmacokinetic Parameters. Started Oct 2006; status: completed.
02
Drugs
valopicitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00395421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395421.